Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype.

Journal of thrombosis and haemostasis : JTH - 1 Feb 2003

Sarkar R, Xiao W, Kazazian H H

Abstract excerpt

A major obstacle for delivery of factor (F)VIII using adeno-associated virus (AAV) vectors is the large size of FVIII cDNA, which is well above the 5 kb packaging limit for AAV. Here we construct a < 5 kb FVIII-AAV vector using murine FVIII cDNA and a strong liver-specific albumin promoter. We assessed the efficacy of this vector using three different routes of administration, intraportal, intrasplenic and tail...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies
Share to Dependovirus
Share to DNA, Complementary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor VIII

Share to Genetic Therapy

Share to Genetic Vectors

Share to Hemophilia A

Share to Mice, Transgenic

Source

Identifiers

PMID: 12871492
DOI: 10.1046/j.1538-7836.2003.00096.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype.PMID 12871492Read ↗

Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII.Semantic proximity Read ↗

Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia ASemantic proximity Read ↗

Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotypeSemantic proximity Read ↗

Current and emerging gene therapies for haemophilia A and BSemantic proximity Read ↗

Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primatesSemantic proximity Read ↗

Low-dose AAV-CRISPR-mediated liver-specific knock-in restored hemostasis in neonatal hemophilia B mice with subtle antibody responseSemantic proximity Read ↗

Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIIISemantic proximity Read ↗

Promoterless gene targeting without nucleases ameliorates haemophilia B in mice.Semantic proximity Read ↗

Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primatesSemantic proximity Read ↗

Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A MiceSemantic proximity Read ↗

Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia ASemantic proximity Read ↗

Pre-clinical evaluation of an enhanced-function factor VIII variant for durable hemophilia A gene therapy in male miceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.